American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

What is the best way to approach burning feet? What is a normal sural response in a 60 year old? Are distal needle findings indicative of a radiculopathy or neuropathy? Tune in to this episode to hear a lively discussion about so many practical challenges faced every day in the EMG laboratory.

Curious about which immunosuppressant is most efficacious for treatment of Myasthenia Gravis? In this episode, Vonda Elmer, R. EEG/EP. T, R. NCS. T, CNCT will talk with Donald Sanders, MD, professor emeritus of neurology at Duke University School of Medicine and lead author of the recently published data from The Duke MG Patient Registry comparing the effectiveness of Azathioprine and Mycophenolate Mofetil in generalized Myasthenia Gravis. Dr. Sanders will share the details and findings of this interesting retrospective single-center review.

In this interview, Dr. Roopa Sharma, MD, interviews with Hans D. Katzberg, MD—Professor of Medicine and Head of the Division of Neurology at University Health Network and the University of Toronto—about his recent article and the AANEM guideline published in Muscle & Nerve, titled “Diagnostic and Screening Laboratory Tests in the Assessment of Patients with Small Fiber Neuropathy: An Evidence-Based Review—Report of the AANEM Small Fiber Neuropathy Task Force.

The electrodiagnostics community diagnoses many entrapment neuropathies, but fixing them is a different story. In this episode, Shawn Jorgensen, MD will interview Berdale Colorado, DO, the lead author of a recent AANEM Expert Clinical Perspective about ultrasound-guided nerve hydrodissection, who will teach us about one non-surgical options for entrapment neuropathies.

Pushpa Narayanaswami, MD presents an overview of infection risks in individuals with neuromuscular disorders (NMDs), including both increased susceptibility to infections and the role of certain infections in triggering NMDs. She will also review evidence on vaccine effectiveness in patients receiving immunosuppressive therapies, and discuss the heightened risk of meningococcal disease in those treated with complement C5 inhibitors (C5ITs), along with key strategies to mitigate this risk. Sponsored by Alexion Pharmaceuticals, Inc.